Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors von Bahleda, R., Meric-Bernstam, F., Goyal, L., Tran, B., He, Y., Yamamiya, I., Benhadji, K.A., Matos, I., Arkenau, H.-T.

Volltext

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience von Olmos, D., Arkenau, H.-T., Ang, J.E., Ledaki, I., Attard, G., Carden, C.P., Reid, A.H.M., A'Hern, R., Fong, P.C., Oomen, N.B., Molife, R., Dearnaley, D., Parker, C., Terstappen, L.W.M.M., de Bono, J.S.

Volltext

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer von Chatterjee, M., Turner, D.C., Felip, E., Lena, H., Cappuzzo, F., Horn, L., Garon, E.B., Hui, R., Arkenau, H.-T., Gubens, M.A., Hellmann, M.D., Dong, D., Li, C., Mayawala, K., Freshwater, T., Ahamadi, M., Stone, J., Lubiniecki, G.M., Zhang, J., Im, E., De Alwis, D.P., Kondic, A.G., Fløtten, Ø.

Volltext

Targeting BRAF for patients with melanoma von Arkenau, H-T, Kefford, R, Long, G V

Volltext

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies von Arkenau, H.-T., Plummer, R., Molife, L.R., Olmos, D., Yap, T.A., Squires, M., Lewis, S., Lock, V., Yule, M., Lyons, J., Calvert, H., Judson, I.

Volltext

Reporting incidental germline variants in the context of day-to-day somatic genomic profiling von Mak, G., Moschetta, M., Arkenau, H.-T.

Volltext

Second primary colorectal cancers (SPCRCs): experiences from a large Australian Cancer Registry von Ringland, C. L., Arkenau, H.-T., O'Connell, D. L., Ward, R. L.

Volltext

The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma von Arkenau, H-T, Chong, G, Cunningham, D, Watkins, D, Agarwal, R, Sirohi, B, Trumper, M, Norman, A, Wotherspoon, A, Horwich, A

Volltext

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours von Arkenau, H.-T., Italiano, A., Mak, G., Toulmonde, M., Baird, R.D., Garcia-Corbacho, J., Plummer, R., Flynn, M., Forster, M., Wilson, R.H., Tosi, D., Adenis, A., Donaldson, K., Posner, J., Kawabata, I., Arimura, A., Deva, S., Spicer, J.

Volltext

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience von Arkenau, H-T, Olmos, D, Ang, J E, de Bono, J, Judson, I, Kaye, S

Volltext

Impact of body composition on survival of PD-1/PD-L1-treated metastatic gastro-esophageal junction/gastric cancer von Morelli, C., Formica, V., Roselli, M., Arkenau, HT

Volltext

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with c... von Tran, B., Meric-Bernstam, F., Arkenau, H.-T., Bahleda, R., Kelley, R.K., Hierro, C., Ahn, D., Zhu, A., Javle, M., Winkler, R., He, H., Huang, J., Goyal, L.

Volltext

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? von Postel-Vinay, S, Arkenau, H-T, Olmos, D, Ang, J, Barriuso, J, Ashley, S, Banerji, U, De-Bono, J, Judson, I, Kaye, S

Volltext

Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA) von Uccello, M, Moschetta, M, Mak, G, Alam, T, Henriquez, C Murias, Arkenau, H-T

Volltext

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study von Tabernero, J., Shitara, K., Zaanan, A., Doi, T., Lorenzen, S., Van Cutsem, E., Fornaro, L., Catenacci, D.V.T., Fougeray, R., Moreno, S.R., Azcue, P., Arkenau, H.-T., Alsina, M., Ilson, D.H.

Volltext

Overall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TA... von Shitara, K., Tabernero, J., Dvorkin, M., Mansoor, W., Arkenau, H.-T., Prokharau, A., Alsina, M., Ghidini, M., Faustino, C., Gorbunova, V., Zhavrid, E., Nishikawa, K., Hosokawa, A., Ganea, D., Yalçın, Ş., Fujitani, K., Beretta, G., Winkler, R., Doi, T., Ilson, D.H.

Volltext

Circulating tumour DNA experience in patients with cancer of unknown primary von Winter, H., Faull, I., Bains, P., Murias, C., Kushnir, M., Forster, M.D., Kulkarni, A., Moore, D., Swanton, C., Shiu, K., Arkenau, H.-T.

Volltext

Match-adjusted indirect comparison of durvalumab and chemotherapy for locally advanced or metastatic urothelial carcinoma (UC) following failure of platinum-based therapy von Hoyle, C.K., Klein, A.B., Patel, K.A., Shire, N., Wang, H., Chu, B.C., Ouwens, M., Nordstrom, B.L., Horne, L., Arkenau, H.-T.

Volltext

A phase I trial of vorolanib (X-82t vascular endothelial growth factor receptor (VEGFR) inhibitor, in patients (pts) with advanced solid tumors von Bendell, J., Moore, K.N., Patel, M.R., Chua, C., Arkenau, H.-T., Dukart, G., Harrow, K., Liang, C.

Volltext

Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours von Bono, P, Massard, C, Peltola, K, Azaro, A, Italiano, A, Kristeleit, R S, Lassen, U N, Arkenau, H-T, Hakulinen, P, Garratt, C, Ikonen, T, Mustonen, M, Rodon, J

Volltext